To read the full story, subscribe or sign in.

Harbour Biomed signs research deal for COVID-19 treatment and files listing application

Aug. 25, 2020

HONG KONG – Last week was a busy one for Harbour Biomed Therapeutics Ltd., seeing the company sign a COVID-19 research collaboration with several Dutch institutions as well as lodge an application to list on the Hong Kong Stock Exchange.

BioWorld Asia Deals and M&A Research Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for Jan. 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 14, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Illustration of cell receptors, antibodies

Abbvie and Simcere enter a $1B T-cell engager deal

BioWorld Asia

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...